Nutriband Inc (NASDAQ:NTRB) — Market Cap & Net Worth
Market Cap & Net Worth: Nutriband Inc (NTRB)
Nutriband Inc (NASDAQ:NTRB) has a market capitalization of $70.50 Million ($70.50 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #20664 globally and #4680 in its home market, demonstrating a 31.90% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nutriband Inc's stock price $7.65 by its total outstanding shares 12155683 (12.16 Million). Also see Nutriband Inc asset portfolio for a full breakdown of the balance sheet.
Nutriband Inc Market Cap History: 2017 to 2026
Nutriband Inc's market capitalization history from 2017 to 2026. Data shows growth from $68.77 Million to $92.99 Million (3.49% CAGR). Also see Nutriband Inc operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
Nutriband Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #592 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #1985 of 3165 |
Weight: Nutriband Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Nutriband Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nutriband Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Nutriband Inc stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
45.66x
Nutriband Inc's market cap is 45.66 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $145.87 Million | $245.28K | -$3.33 Million | 594.69x | N/A |
| 2020 | $156.29 Million | $370.65K | -$2.80 Million | 421.66x | N/A |
| 2021 | $105.03 Million | $943.70K | -$3.21 Million | 111.29x | N/A |
| 2022 | $43.82 Million | $1.42 Million | -$8.42 Million | 30.81x | N/A |
| 2023 | $28.20 Million | $2.08 Million | -$4.81 Million | 13.56x | N/A |
| 2024 | $57.25 Million | $2.09 Million | -$5.49 Million | 27.46x | N/A |
| 2025 | $55.19 Million | $2.14 Million | -$10.48 Million | 25.79x | N/A |
| 2026 | $92.99 Million | $2.04 Million | -$8.23 Million | 45.66x | N/A |
Competitor Companies of NTRB by Market Capitalization
Companies near Nutriband Inc in the global market cap rankings as of September 18, 2026. Review NTRB intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Nutriband Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Nutriband Inc Historical Marketcap From 2017 to 2026
Between 2017 and today, Nutriband Inc's market cap moved from $68.77 Million to $ 92.99 Million, with a yearly change of 3.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $92.99 Million | +68.50% |
| 2025 | $55.19 Million | -3.61% |
| 2024 | $57.25 Million | +103.02% |
| 2023 | $28.20 Million | -35.64% |
| 2022 | $43.82 Million | -58.28% |
| 2021 | $105.03 Million | -32.80% |
| 2020 | $156.29 Million | +7.14% |
| 2019 | $145.87 Million | -59.06% |
| 2018 | $356.34 Million | +418.18% |
| 2017 | $68.77 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Nutriband Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $70.50 Million USD |
| MoneyControl | $70.50 Million USD |
| MarketWatch | $70.50 Million USD |
| marketcap.company | $70.50 Million USD |
| Reuters | $70.50 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nutriband Inc
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company… Read more